Cervical cancer vaccine in China for 10 years, but the United States has just listed delisting winflash

Cervical cancer vaccine in Chinese waited for 10 years but was just listed the United States withdraw the original title: wait for 10 years just in Chinese HPV vaccine was listed by the United States delisting from the U.S. Centers for Disease Control and Prevention (CDC) since April 2016, only the purchase of HPV vaccine at 9, mainly in the two dose immunization programs help to improve the vaccination rate. 2016 before the end of the year, the 2 price and the price of 4 HPV vaccine will no longer supply the U.S. market. And so on 10 years of cervical cancer vaccine, just listed on the delisting, the news is once again let the Chinese tangle. In July 12, 2016, the State Food and Drug Administration approved GlaxoSmithKline (GSK) for the prevention of biological products "human papilloma virus vaccine adsorbed" Siri optimal import registration. This product is made by baculovirus expression system respectively expression of L1 virus like particles, and type 18 recombinant HPV16 purified bivalent vaccine, adding MPL and aluminum hydroxide adjuvant preparation etc.. The vaccine is the first to apply for a new vaccine to be listed in China, the study data show that the safety and effectiveness of the application of the target population in China and abroad are consistent. The approval of the vaccine provides a new and effective means for the prevention of cervical cancer in china. "I waited 10 years, because the clinical trial of the vaccine in China has been added, did not get the desired data in clinic, now, so it is not an official approval, not to suppress the batch number." An expert involved in the examination and approval. Human papillomavirus (HPV) is one of the members of the family HPV. At present, there are more than 100 different types of HPV, most of which are regarded as "low risk" of HPV type, and there is no association with cervical cancer. However, there are 14 types of HPV that are classified as "high risk" and have been shown to cause almost all cervical cancers. Among them, two kinds of virus strains with the highest risk of type HPV-16 and type HPV-18 can cause about 70% of cervical cancer cases. HPV infection is now an international consensus on whether it is an epidemiological or clinical data that HPV is a necessary condition for cervical cancer. The first HPV is a key factor to cause cervical cancer scientists in Germany in 2008 – zur hausen was awarded the Nobel prize in physiology. On the basis of their research, scientists have developed HPV prophylactic vaccine to prevent the occurrence of cervical cancer. After the approval of the vaccine, the country does not have mandatory vaccination, voluntary principle." The above experts said. In October 2009, the Japanese Ministry of Health approved the vaccine for cervical cancer, the same year domestic sales began in December. In November 2010 to provide public subsidies for vaccination, April 2013 will be set as regular vaccination, a total of 3 million 390 thousand people were. However, after inoculation said health damage women appear constantly, as of the end of April 2016, received a total of 2945 people reported side effects. "2 price and the price of cervical cancer vaccine, vaccination in the United States in children is not very ideal, to be vaccinated three times, the price of the vaccine was only vaccinated two times, which may also be a reason for the 9 time," said dr.." A theory相关的主题文章: